Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Roberto Ria, Assunta Melaccio, Vito Racanelli, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 6, pp. 1765-1765
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Multiple myeloma: signaling pathways and targeted therapy
Qizhong Lu, Donghui Yang, Hexian Li, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 18
Advancements in Multiple Myeloma Therapies: A Comprehensive Review by Disease Stage
Hager Hisham El Khatib, Хамдан Абдулла, Layla Khaled Nassar, et al.
Lymphatics (2025) Vol. 3, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer
Panagiotis Ntellas, Leonidas Mavroeidis, Stefania Gκoura, et al.
Cancers (2020) Vol. 12, Iss. 11, pp. 3145-3145
Open Access | Times Cited: 54
A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: from molecular interactions to potential therapeutic targets
Mina Alimohammadi, Payman Rahimzadeh, Ramin Khorrami, et al.
Pathology - Research and Practice (2024) Vol. 260, pp. 155401-155401
Closed Access | Times Cited: 8
Role of hypoxia in inhibiting dendritic cells by VEGF signaling in tumor microenvironments: mechanism and application.
Ziying Han, Yucheng Dong, Jizhou Lu, et al.
American Journal of Cancer Research (2021) Vol. 11, Iss. 8, pp. 3777-3793
Closed Access | Times Cited: 38
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications
Emanuele Cencini, Anna Sicuranza, Sara Ciofini, et al.
Current Oncology (2023) Vol. 30, Iss. 7, pp. 6111-6133
Open Access | Times Cited: 15
Multiple Myeloma
Mary C. Vrtis
Home Healthcare Now (2024) Vol. 42, Iss. 3, pp. 140-149
Closed Access | Times Cited: 5
ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and Myeloma Stem Cell Phenotype
Tingting Yu, Lan Yao, Hua Yin, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 6, pp. 2235-2248
Open Access | Times Cited: 20
Anti-Angiogenic Activity of Drugs in Multiple Myeloma
Ilaria Saltarella, Concetta Altamura, Carmen Campanale, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1990-1990
Open Access | Times Cited: 11
Macrofocal multiple myeloma in the era of novel agents in China
Xuelin Dou, Ruixia Liu, Liu Yang, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial
Rowan Kuiper, Sonja Zweegman, Mark van Duin, et al.
Blood Advances (2020) Vol. 4, Iss. 24, pp. 6298-6309
Open Access | Times Cited: 29
Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
Kazuhito Suzuki, Kaichi Nishiwaki, Shingo Yano
Cancers (2021) Vol. 13, Iss. 2, pp. 215-215
Open Access | Times Cited: 25
Pathways of Angiogenic and Inflammatory Cytokines in Multiple Myeloma: Role in Plasma Cell Clonal Expansion and Drug Resistance
Assunta Melaccio, Antonia Reale, Ilaria Saltarella, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6491-6491
Open Access | Times Cited: 16
Prognostic and Therapeutic Role of Angiogenic Microenvironment in Thyroid Cancer
Assunta Melaccio, Lucia Ilaria Sgaramella, Alessandro Pasculli, et al.
Cancers (2021) Vol. 13, Iss. 11, pp. 2775-2775
Open Access | Times Cited: 17
What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma
Bruno Almeida Costa, Tarek H. Mouhieddine, Joshua Richter
Targeted Oncology (2022) Vol. 17, Iss. 4, pp. 383-405
Closed Access | Times Cited: 12
The multifunctional role of Notch signaling in multiple myeloma
Hayley M. Sabol, Jesús Delgado‐Calle
Journal of Cancer Metastasis and Treatment (2021)
Open Access | Times Cited: 13
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
Stefan Knop, Monika Szarejko, Norbert Grząśko, et al.
eJHaem (2024) Vol. 5, Iss. 5, pp. 940-950
Open Access | Times Cited: 1
A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments
Rosario Hervás-Salcedo, Beatriz Martín-Antonio
Cancers (2022) Vol. 14, Iss. 15, pp. 3796-3796
Open Access | Times Cited: 7
Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth
Meng Gao, Hang Dong, Siyi Jiang, et al.
Oncogenesis (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
Lipid levels and multiple myeloma risk: insights from Meta-analysis and mendelian randomization
Weiwei Zhu, Alice Charwudzi, Qian Li, et al.
Lipids in Health and Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 1
Animal Models of Multiple Myeloma Bone Disease
Syed Hassan Mehdi, Sana Nafees, Syed Jafar Mehdi, et al.
Frontiers in Genetics (2021) Vol. 12
Open Access | Times Cited: 9
Bone marrow microenvironment- induced regulation of Bcl-2 family members in multiple myeloma (MM): Therapeutic implications
Osman Aksoy, Judith Lind, Vincent Sunder-Plaßmann, et al.
Cytokine (2022) Vol. 161, pp. 156062-156062
Open Access | Times Cited: 6
A New Clock is Running for Multiple Myeloma: Circadian Clock Protein-Period 3 (PER-3) Polymorphism
İstemi Serin, Mustafa Pehlıvan, İbrahim Halil Demir, et al.
Balkan Journal of Medical Genetics (2022) Vol. 25, Iss. 2, pp. 37-43
Open Access | Times Cited: 4
The Involvement of LAG-3positive Plasma Cells in the Development of Multiple Myeloma
Natalia Kreiniz, Nasren Eiza, Tamar Tadmor, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 549-549
Open Access | Times Cited: 2
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma
Nicolas Thomas Iannozzi, Valentina Marchica, Denise Toscani, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15448-15448
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top